

GASTROİNTESTİNAL SİSTEM EOZİNOFİLİK HASTALIKLARI

Haydar Güven KAYALI¹ - Mete AKIN²

DOI: 10.37609/akya.3785.c454

GİRİŞ

Eozinofilik gastrointestinal hastalıklar (EGİH), eozinofilik özofajit (EoÖ), eozinofilik gastrit (EoG), eozinofilik enterit (EoE), eozinofilik kolit (EoK) gibi histolojik olarak eozinofillerden baskın inflamasyon ve klinik olarak gastrointestinal semptomlarla karakterize kronik, immün aracılı bir grup hastalığı tanımlayan bir terimdir. Primer veya sekonder olarak görülebilir. Eozinofilik özofajit genellikle ayrı bir klinik antite olarak ele alınmaktadır. Ancak bazı hastalarda özofagus da dahil olmak üzere gastrointestinal sistemde birden fazla lokalizasyonda eş zamanlı tutulum görülebilir. Bu bölümde EGİH'lerin klinik belirtileri, tanı ve tedavisi gözden geçirilmiştir.

SAĞLIKLI BİREYDE VE EGİH'DE EOZİNOFİL BİYOLOJİSİ

Eozinofiller, nötrofiller ve bazofiller gibi granülositik seride yer alan beyaz kan hücreleridir. Eozinofillerin fizyolojik işlevleri tümüyle aydınlatılmamış olsa da enfeksiyona karşı immün yanıtta, doku yeniden yapılanmasında rol oynadıkları ve diğer immün sistem hücreleriyle etkileşimde oldukları bilinmektedir. Eozinofiller, interlökin (IL)

5, IL-3 ve granülosit-makrofaj koloni uyarıcı faktörünün (GM-CSF) etkisi altında kemik iliğinde gelişir ve farklılaşır (1).

Periferik kanda eozinofili, eozinofil yüzdesi eşliğinden ziyade mutlak eozinofil sayısı (MES) ile daha iyi tanımlanır. MES'in 500 hücre/mikrolitre'ye ($\leq 0.5 \times 10^9/L$) kadar olması genellikle normal kabul edilir. Eozinofiller esas olarak dokularda bulunan hücreler olup dokulardaki sayıları kandaki sayıya göre birkaç yüz kat fazladır. Sağlıklı bireylerde eozinofiller dalak, lenf nodları, timus ve gastrointestinal sistemde (özofagus hariç) bulunabilir. Dokulara eozinofillerin göçü, eozinofil kemokin reseptörü CCR3'e bağlanan ve hücre göçünü uyaran sitokinler olan eotaksinler tarafından gerçekleştirilir (2).

Eozinofiller, intestinal epitel dahil çeşitli dokulara toksik proteinler içeren özel ikincil granüllere sahiptir. Eozinofil granülleri, majör bazik protein (MBP)-1 ve MBP-2'den oluşan bir kristaloid çekirdek ve eozinofil katyonik protein (EKP), eozinofil kaynaklı nörotoksin ve eozinofil peroksidazdan oluşan bir matriks içerir (3).

Klinik deneylerde, eozinofilik gastroenteriti olan hastaların ince bağırsağında MBP ve EKP'nin ekstraselüler birikimi gösterilmiştir. Eozinofil kaynaklı nörotoksinin dolaşımdaki seviyeleri de EoÖ

¹ Uzm. Dr., Sağlık Bilimleri Üniversitesi, Ankara Etlik Şehir Hastanesi, Gastroenteroloji Kliniği, Gastroenteroloji Yandal Asistanı, hgkayali@gmail.com, ORCID iD: 0000-0002-2877-3561

² Prof. Dr., Antalya Medical Park Hastanesi, Mudanya Üniversitesi Sağlık Bilimleri Fakültesi, Gastroenteroloji Kliniği, drmeteakin@yahoo.com, ORCID iD: 0000-0003-2393-7990

KAYNAKLAR

- Klion AD, Ackerman SJ, Bochner BS. Contributions of Eosinophils to Human Health and Disease. *Annual Review of Pathology*. 2020;5: 179-209. doi: 10.1146/annurev-pathmechdis-012419-032756
- Constantine GM, Klion AD. Recent advances in understanding the role of eosinophils. *Faculty Reviews*. 2022;11: 26. doi: 10.12703/r/11-26
- Mishra A, Hogan SP, Lee JJ, et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. *Journal of Clinical Investigation*. 1999;103(12): 1719-1727. doi: 10.1172/JCI6560
- Saffari H, Hoffman LH, Peterson KA, et al. Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis. *Journal of Allergy and Clinical Immunology*. 2014;133(6): 1728-1734. doi: 10.1016/j.jaci.2013.11.024
- Zhu X, Wang M, Mavi P, et al. Interleukin-5 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice. *Gastroenterology*. 2010;139(1): 182-193. doi: 10.1053/j.gastro.2010.03.057
- Zuo L, Fulkerson PC, Finkelman FD, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. *Journal of Immunology*. 2010; 185(1):660-669. doi: 10.4049/jimmunol.1000471
- Furuta GT, Straumann A. Review article: the pathogenesis and management of eosinophilic oesophagitis. *Alimentary Pharmacology and Therapeutics*. 2006;24(2): 173-182. doi: 10.1111/j.1365-2036.2006.02984.x
- Gupta SK, Fitzgerald JF, Kondratyuk T, et al. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. *Journal of Pediatric Gastroenterology and Nutrition*. 2006;42(1): 22-26. doi: 10.1097/01.mpg.0000188740.38757.d2
- Brusilovsky M, Bao R, Rochman M, et al. Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. *Gastroenterology*. 2022;162(2): 521-534. doi: 10.1053/j.gastro.2021.10.002
- Lu TX, Sherrill JD, Wen T, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. *Journal of Allergy and Clinical Immunology*. 2012;129(4): 1064-1075. doi: 10.1016/j.jaci.2012.01.060
- Liaccouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *The Journal of Allergy and Clinical Immunology*. 2011;128(1): 3-20. doi: 10.1016/j.jaci.2011.02.040
- Arias Á, Lucendo AJ. Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. *Expert Review of Gastroenterology and Hepatology*. 2020;14(11): 1069-1082. doi: 10.1080/17474124.2020.1806054
- Navarro P, Arias Á, Arias-González L, et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. *Alimentary Pharmacology and Therapeutics*. 2019;49(9): 1116-1125. doi: 10.1111/apt.15231
- Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United States. *Clinical Gastroenterology and Hepatology*. 2014;12(4):589-596. doi: 10.1016/j.cgh.2013.09.008
- van Rhijn BD, Verheij J, Smout AJPM, et al. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. *Neurogastroenterology and Motility*. 2013;25(1): 47-52.e5. doi: 10.1111/nmo.12009
- Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. *Clinical Gastroenterology and Hepatology*. 2009;7(10): 1055-1601. doi: 10.1016/j.cgh.2009.06.023
- Syed AAN, Andrews CN, Shaffer E, et al. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. *Alimentary Pharmacology and Therapeutics*. 2012;36(10): 950-958. doi: 10.1111/apt.12053
- Arias Á, Pérez-Martínez I, Tenías JM, et al. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. *Alimentary Pharmacology and Therapeutics*. 2016;43(1): 3-15. doi: 10.1111/apt.13441
- Moawad FJ, Veerappan GR, Lake JM, et al. Correlation between eosinophilic oesophagitis and aeroallergens. *Alimentary Pharmacology and Therapeutics*. 2010;31(4): 509-515. doi: 10.1111/j.1365-2036.2009.04199.x
- Leigh LY, Spergel JM. An in-depth characterization of a large cohort of adult patients with eosinophilic esophagitis. *Annals of Allergy, Asthma, and Immunology*. 2019;122(1): 65-72.e1. doi: 10.1016/j.anai.2018.09.452
- Hill DA, Grundmeier RW, Ramos M, et al. Eosinophilic esophagitis is a late manifestation of the allergic march. *The Journal of Allergy and Clinical Immunology. In practice*. 2018;6(5): 1528-1533. doi: 10.1016/j.jaip.2018.05.010
- O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. *Gastroenterology*. 2018;154(2): 333-345. doi: 10.1053/j.gastro.2017.06.065
- Koutlas NT, Eluri S, Rusin S, et al. Impact of smoking, alcohol consumption, and NSAID use on risk for and phenotypes of eosinophilic esophagitis. *Diseases of the Esophagus*. 2018;31(1): 1-7. doi: 10.1093/dote/dox111
- Witmer CP, Susi A, Min SB, et al. Early Infant Risk Factors for Pediatric Eosinophilic Esophagitis. *Journal of Pediatric Gastroenterology and Nutrition*. 2018;67(5): 610-615. doi: 10.1097/MPG.00000000000002123
- Jensen ET, Kuhl JT, Martin LJ, et al. Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis. *The Journal of Allergy and Clinical Immunology*. 2018; 141(2): 632-637.e5. doi: 10.1016/j.jaci.2017.07.010
- Shah SC, Tepler A, Peek RM Jr, et al. Association Between *Helicobacter pylori* Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*. 2019;17(11): 2185-2198. doi: 10.1016/j.cgh.2019.01.013
- Molina-Infante J, Gutierrez-Junquera C, Savarino E, et al. *Helicobacter pylori* infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. *The American Journal of Gastroenterology*. 2018;113(7): 972-979. doi: 10.1038/s41395-018-

- 0035-6
28. O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. *Gastroenterology*. 2018;154(2): 333-345. doi: 10.1053/j.gastro.2017.06.065
29. Racca F, Pellegatta G, Cataldo G, et al. Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets. *Frontiers in Physiology*. 2022;12: 815842. doi:10.3389/fphys.2021.815842
30. Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response. *The Journal of Allergy and Clinical Immunology*. 2001;108(6): 954-961. doi: 10.1067/mai.2001.119917
31. Shoda T, Wen T, Aceves SS, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. *Lancet Gastroenterology and Hepatology*. 2018; 3(7): 477-488. doi: 10.1016/S2468-1253(18)30096-7
32. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). *The American Journal of Gastroenterology*. 2013;108(5): 679-692. doi: 10.1038/ajg.2013.71
33. Gupta M, Grinman M. Diagnosis and management of eosinophilic esophagitis. *Canadian Medical Association Journal*. 2024;196(4): E121-128. doi: 10.1503/cmaj.230378
34. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. *Journal of Pediatric Gastroenterology and Nutrition*. 2009;48(1): 30-36. doi: 10.1097/MPG.0b013e3181788282
35. Mukkada VA, Haas A, Maune NC, et al. Feeding dysfunction in children with eosinophilic gastrointestinal diseases. *Pediatrics*. 2010; 126(3): e672-677. doi: 10.1542/peds.2009-2227
36. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*. 2018;155(4): 1022-1033. doi: 10.1053/j.gastro.2018.07.009
37. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. *Clinical Gastroenterology and Hepatology*. 2009;7(2): 1305-1313. doi: 10.1016/j.cgh.2009.08.030
38. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. *Gut*. 2013;62(4): 489-495. doi: 10.1136/gutjnl-2011-301817
39. Kim HP, Vance RB, Shaheen NJ, et al. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. *Clinical Gastroenterology and Hepatology*. 2012;10(9): 988-996.e5. doi: 10.1016/j.cgh.2012.04.019
40. Pouw RE, Barret M, Biermann K, et al. Endoscopic tissue sampling-Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*. 2021;53(11): 1174-1188. doi: 10.1055/a-1611-5091
41. Collins MH. Histopathology of eosinophilic esophagitis. *Digestive Diseases*. 2014;32(1-2): 68-73. doi: 10.1159/000357012.
42. Dhar A, Haboubi HN, Attwood SE, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. *Gut*. 2022;71(8): 1459-1487. doi: 10.1136/gutjnl-2022-327326
43. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. *Clinical Gastroenterology and Hepatology*. 2006;4 (9): 1097-1102. doi: 10.1016/j.cgh.2006.05.026
44. Arias A, González-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. *Gastroenterology*. 2014;146(7): 1639-1648. doi: 10.1053/j.gastro.2014.02.006
45. Hoofien A, Dias JA, Malamisura M, et al. Pediatric eosinophilic esophagitis: results of the European retrospective pediatric eosinophilic esophagitis registry (RetroPEER). *Journal of Pediatric Gastroenterology and Nutrition*. 2019;68(4): 552-558. doi: 10.1097/MPG.0000000000002215
46. Molina-Infante J, Arias A, Barrio J, et al. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. *The Journal of Allergy and Clinical Immunology*. 2014;134(5): 1093-1099.e1. doi: 10.1016/j.jaci.2014.07.023
47. Molina-Infante J, Arias Ángel, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. *The Journal of Allergy and Clinical Immunology*. 2018;141(4): 1365-1372. doi: 10.1016/j.jaci.2017.08.038
48. Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*. 2016;14(1): 13-22.e1. doi: 10.1016/j.cgh.2015.07.041
49. Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. *Alimentary Pharmacology and Therapeutics*. 2020;52(5): 798-807. doi: 10.1111/apt.15957
50. Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. *Alimentary Pharmacology and Therapeutics*. 2015;41(9): 797-806. doi: 10.1111/apt.13147
51. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. *Gastroenterology* 2020;158(1): 111-122.e10. doi: 10.1053/j.gastro.2019.09.042
52. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. *The New England Journal of Medicine*. 2022;387(25): 2317-2330. doi: 10.1056/NEJMoa2205982
53. Jacobs JW, Spechler SJ. A systematic review of the risk of

- perforation during esophageal dilation for patients with eosinophilic esophagitis. *Digestive Diseases and Sciences* 2010;55(6): 1512–1515. doi: 10.1007/s10620-010-1165-x.
54. Moawad FJ, Molina-Infante J, Lucendo AJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. *Alimentary Pharmacology and Therapeutics*. 2017;46(2): 96–105. doi: 10.1111/apt.14123
 55. Leiman DA, Kamal AN, Otaki F, et al. Quality indicators for the diagnosis and management of eosinophilic esophagitis. *The American Journal of Gastroenterology*. 2023;118(6): 1091–1095. doi: 10.14309/ajg.0000000000002138
 56. von Arnim U, Biedermann L, Aceves SS, et al. Monitoring patients with eosinophilic esophagitis in routine clinical practice: international expert recommendations. *Clinical Gastroenterology and Hepatology*. 2023;21(10): 2526–2533. doi: 10.1016/j.cgh.2022.12.018
 57. Dellon ES, Gonsalves N, Abonia JP, et al. International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. *Clinical Gastroenterology and Hepatology*. 2022;20(11): 2474–2484. doi: 10.1016/j.cgh.2022.02.017
 58. Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. *Gastroenterology Clinics of North America*. 2014;43(2): 257–268. doi: 10.1016/j.gtc.2014.02.007
 59. Talley NJ, Shorter RG, Phillips SF, et al. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. *Gut*. 1990; 31(1): 54–58. doi: 10.1136/gut.31.1.54
 60. Jensen ET, Martin CF, Kappelman MD, et al. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. *Journal of Pediatric Gastroenterology and Nutrition*. 2016;62(1): 36–42. doi: 10.1097/MPG.0000000000000865
 61. Gonsalves N, Doerfler B, Yang G, et al. A prospective clinical trial of six food elimination diet or elemental diet in the treatment of adults with eosinophilic gastroenteritis. *Gastroenterology*. 2009;136: S1861.
 62. Zalewski A, Gonsalves N, Doerfler B, et al. Results from the element study: Prospective study of elemental diet in eosinophilic gastroenteritis nutrition trial. AGA Abstracts. *Gastroenterology*. 2020;158: S43.
 63. Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. *The Journal of Allergy and Clinical Immunology*. 2009;124(6): 1326–1332. doi: 10.1016/j.jaci.2009.09.048
 64. Matsushita M, Hajiro K, Morita Y, et al. Eosinophilic gastroenteritis involving the entire digestive tract. *The American Journal of Gastroenterology*. 1995;90(10): 1868–1870.
 65. Chen MJ, Chu CH, Lin SC, et al. Eosinophilic gastroenteritis: clinical experience with 15 patients. *World Journal of Gastroenterology*. 2003;9(12): 2813–2816. doi: 10.3748/wjg.v9.i12.2813
 66. Hirano I, Collins MH, King E, et al. Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. *The American Journal of Gastroenterology*. 2022;117(3): 413–423. doi: 10.14309/ajg.0000000000001625
 67. Dellon ES, Gonsalves N, Rothenberg ME, et al. Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. *Clinical Gastroenterology and Hepatology*. 2022;20(3): 535–545. doi: 10.1016/j.cgh.2021.05.053
 68. Yamamoto M, Nagashima S, Yamada Y, et al. Comparison of Nonesophageal Eosinophilic Gastrointestinal Disorders with Eosinophilic Esophagitis: A Nationwide Survey. *Journal of Allergy and Clinical Immunology. In Practice*. 2021;9(9): 3339–3349. doi: 10.1016/j.jaip.2021.06.026
 69. Spergel JM, Shuker M. Nutritional management of eosinophilic esophagitis. *Gastrointestinal Endoscopy Clinics of North America*. 2008;18(1): 179–194. doi: 10.1016/j.giec.2007.09.008
 - Lee CM, Changchien CS, Chen PC, et al. Eosinophilic gastroenteritis: 10 years experience. *The American Journal of Gastroenterology*. 1993;88(1): 70–74.